{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:27Z","timestamp":1772165667623,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["81903371"],"award-info":[{"award-number":["81903371"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"crossref","award":["R34MH119963"],"award-info":[{"award-number":["R34MH119963"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the National Science and Technology Major Project","award":["2018ZX10101-001-001-003"],"award-info":[{"award-number":["2018ZX10101-001-001-003"]}]},{"name":"Special Found on Prevention and Control of New Coronary Pneumonia in Guangdong Universities","award":["2020KZDZX1047"],"award-info":[{"award-number":["2020KZDZX1047"]}]},{"name":"Medical Science and Technology Innovation Platform Support Project of Zhongnan Hospital, Wuhan University","award":["PTXM2020008"],"award-info":[{"award-number":["PTXM2020008"]}]},{"name":"Science and Technology Innovation Cultivation Fund of Zhongnan Hospital, Wuhan University","award":["cxpy2017043"],"award-info":[{"award-number":["cxpy2017043"]}]},{"name":"Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University","award":["TFJC2018004"],"award-info":[{"award-number":["TFJC2018004"]}]},{"name":"the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences","award":["2020-PT320-004"],"award-info":[{"award-number":["2020-PT320-004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Research on the immune response to inactivated COVID-19 vaccination among people living with HIV (PLWH) is limited, especially among those with low CD4+\u2009T lymphocyte (CD4 cell) count. This prospective cohort study aimed to assess the humoral immune response to inactivated COVID-19 vaccination among PLWH compared to HIV negative controls (HNCs) and to determine the impact of CD4 cell count on vaccine response among PLWH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The neutralizing antibodies (nAbs) and the specific IgM and IgG-binding antibody responses to the inactivated COVID-19 vaccine at the third month after the second dose of inactivated COVID-19 vaccination were measured among 138 PLWH and 35 HNCs. Multivariable logistic regression and multiple linear regression models were conducted to identify factors associated with the seroconversion rate of antibodies and the magnitude of anti-SARS-CoV-2 antibody titers, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At the end of the third month after two doses of vaccination, the seroconversion rates of IgG were comparable between PLWH (44.9%; 95% CI 36.5\u201353.3%) and HNCs (60.0%; 95% CI 42.9\u201377.1%), respectively. The median titers and seroconversion rate of nAbs among PLWH were 0.57 (IQR: 0.30\u20131.11) log\n                      <jats:sub>10<\/jats:sub>\n                      BAU\/mL and 29.0% (95% CI 21.3\u201336.8%), respectively, both lower than those in HNCs (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). After adjusting for age, sex, comorbidities, and CD4 cell count, the titers and seroconversion rate of nAbs were comparable between PLWH and HNCs (P\u2009&gt;\u20090.05). Multivariable regression analyses showed that CD4 cell count\u2009&lt;\u2009200\/\u03bcL was independently associated with lower titers and seroconversion rate of nAbs among PLWH (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). A positive correlation was observed between the CD4 cell count and nAbs titers in PLWH (Spearman's \u03c1\u2009=\u20090.25,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0034).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study concluded that the immune response to inactivated COVID-19 vaccination among PLWH was independently associated with CD4 cell count, PLWH with lower CD4 cell count showed a weaker humoral immune response, especially those with CD4 cell count\u2009&lt;\u2009200\/\u03bcL. This finding suggests that expanding COVID-19 vaccination coverage among PLWH is impendency. In addition, aggressive ART should be carried out for PLWH, especially for those with low CD4 cell count, to improve the immune response to vaccines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-023-07982-x","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T21:26:33Z","timestamp":1674249993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV"],"prefix":"10.1186","volume":"23","author":[{"given":"Songjie","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangzhao","family":"Ming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengmeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyuan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiming","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"issue":"18","key":"7982_CR1","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2020.6019","volume":"323","author":"JM Sanders","year":"2020","unstructured":"Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824\u201336. https:\/\/doi.org\/10.1001\/jama.2020.6019.","journal-title":"JAMA"},{"key":"7982_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09540121.2022.2052259","volume":"23","author":"W Guo","year":"2022","unstructured":"Guo W, Ming F, Dong Y, Zhang Q, Liu L, Gao M, et al. Driving force of Covid-19 among people living with HIV\/AIDS in Wuhan. China AIDS Care. 2022;23:1\u20138. https:\/\/doi.org\/10.1080\/09540121.2022.2052259.","journal-title":"China AIDS Care"},{"issue":"11","key":"7982_CR3","doi-asserted-by":"publisher","first-page":"e690","DOI":"10.1016\/s2352-3018(21)00239-3","volume":"8","author":"X Yang","year":"2021","unstructured":"Yang X, Sun J, Patel RC, Zhang J, Guo S, Zheng Q, et al. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. Lancet HIV. 2021;8(11):e690\u2013700. https:\/\/doi.org\/10.1016\/s2352-3018(21)00239-3.","journal-title":"Lancet HIV."},{"issue":"2","key":"7982_CR4","doi-asserted-by":"publisher","first-page":"e2037069","DOI":"10.1001\/jamanetworkopen.2020.37069","volume":"4","author":"JM Tesoriero","year":"2021","unstructured":"Tesoriero JM, Swain CE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State. JAMA Netw Open. 2021;4(2):e2037069. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.37069.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"7982_CR5","doi-asserted-by":"publisher","first-page":"e2095","DOI":"10.1093\/cid\/ciaa1605","volume":"73","author":"AM Geretti","year":"2021","unstructured":"Geretti AM, Stockdale AJ, Kelly SH, Cevik M, Collins S, Waters L, et al. Outcomes of coronavirus disease 2019 (COVID-19) related hospitalization among people with human immunodeficiency virus (HIV) in the ISARIC World Health Organization (WHO) clinical characterization protocol (UK): a prospective observational study. Clin Infect Dis. 2021;73(7):e2095\u2013106. https:\/\/doi.org\/10.1093\/cid\/ciaa1605.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"7982_CR6","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3018(20)30305-2","volume":"8","author":"K Bhaskaran","year":"2021","unstructured":"Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2021;8(1):e24\u201332. https:\/\/doi.org\/10.1016\/S2352-3018(20)30305-2.","journal-title":"Lancet HIV."},{"issue":"7","key":"7982_CR7","doi-asserted-by":"publisher","first-page":"e2005","DOI":"10.1093\/cid\/ciaa1198","volume":"73","author":"Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases SA","year":"2021","unstructured":"Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases SA. Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis. 2021;73(7):e2005\u201315. https:\/\/doi.org\/10.1093\/cid\/ciaa1198.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"7982_CR8","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.cmi.2021.07.031","volume":"27","author":"I Levy","year":"2021","unstructured":"Levy I, Wieder-Finesod A, Litchevsky V, Biber A, Indenbaum V, Olmer L, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clin Microbiol Infect. 2021;27(12):1851\u20135. https:\/\/doi.org\/10.1016\/j.cmi.2021.07.031.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"7982_CR9","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1093\/cid\/ciab648","volume":"74","author":"BA Woldemeskel","year":"2022","unstructured":"Woldemeskel BA, Karaba AH, Garliss CC, Beck EJ, Wang KH, Laeyendecker O, et al. The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with human immunodeficiency virus (HIV). Clin Infect Dis. 2022;74(7):1268\u201370. https:\/\/doi.org\/10.1093\/cid\/ciab648.","journal-title":"Clin Infect Dis"},{"issue":"14","key":"7982_CR10","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1097\/QAD.0000000000003017","volume":"35","author":"JA Ruddy","year":"2021","unstructured":"Ruddy JA, Boyarsky BJ, Bailey JR, Karaba AH, Garonzik-Wang JM, Segev DL, et al. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV. AIDS. 2021;35(14):2399\u2013401. https:\/\/doi.org\/10.1097\/QAD.0000000000003017.","journal-title":"AIDS"},{"issue":"11","key":"7982_CR11","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1097\/qad.0000000000002945","volume":"35","author":"JA Ruddy","year":"2021","unstructured":"Ruddy JA, Boyarsky BJ, Werbel WA, Bailey JR, Karaba AH, Garonzik-Wang JM, et al. Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV. AIDS. 2021;35(11):1872\u20134. https:\/\/doi.org\/10.1097\/qad.0000000000002945.","journal-title":"AIDS"},{"issue":"9","key":"7982_CR12","doi-asserted-by":"publisher","first-page":"e568","DOI":"10.1016\/S2352-3018(21)00157-0","volume":"8","author":"SA Madhi","year":"2021","unstructured":"Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B\/2A trial. Lancet HIV. 2021;8(9):e568\u201380. https:\/\/doi.org\/10.1016\/S2352-3018(21)00157-0.","journal-title":"Lancet HIV."},{"issue":"8","key":"7982_CR13","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S2352-3018(21)00103-X","volume":"8","author":"J Frater","year":"2021","unstructured":"Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2\/3 clinical trial. Lancet HIV. 2021;8(8):e474\u201385. https:\/\/doi.org\/10.1016\/S2352-3018(21)00103-X.","journal-title":"Lancet HIV."},{"key":"7982_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1008","author":"K Khan","year":"2021","unstructured":"Khan K, Lustig G, Bernstein M, Archary D, Cele S, Karim F, et al. Immunogenicity of SARS-CoV-2 infection and Ad26.CoV2.S vaccination in people living with HIV. Clin Infect Dis. 2021. https:\/\/doi.org\/10.1093\/cid\/ciab1008.","journal-title":"Clin Infect Dis"},{"key":"7982_CR15","doi-asserted-by":"publisher","first-page":"108383","DOI":"10.1016\/j.intimp.2021.108383","volume":"102","author":"Z Lv","year":"2022","unstructured":"Lv Z, Li Q, Feng Z, Zheng X, Nayin, Yang H, et al. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV. Int Immunopharmacol. 2022;102:108383. https:\/\/doi.org\/10.1016\/j.intimp.2021.108383.","journal-title":"Int Immunopharmacol"},{"key":"7982_CR16","doi-asserted-by":"publisher","first-page":"101226","DOI":"10.1016\/j.eclinm.2021.101226","volume":"43","author":"Y Feng","year":"2022","unstructured":"Feng Y, Zhang Y, He Z, Huang H, Tian X, Wang G, et al. Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study. EClinicalMedicine. 2022;43:101226. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101226.","journal-title":"EClinicalMedicine."},{"key":"7982_CR17","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2020.15543","volume":"324","author":"S Xia","year":"2020","unstructured":"Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324:951\u201360.","journal-title":"JAMA"},{"key":"7982_CR18","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1080\/22221751.2020.1852059","volume":"9","author":"ZJ Wang","year":"2020","unstructured":"Wang ZJ, Zhang HJ, Lu J, Xu KW, Peng C, Guo J, et al. Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models. Emerg Microbes Infect. 2020;9:2606\u201318.","journal-title":"Emerg Microbes Infect"},{"key":"7982_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","volume":"326","author":"KN Al Kaabi","year":"2021","unstructured":"Al Kaabi KN, Zhang Y, Xia S, Yang Y, Al QM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326:35\u201345.","journal-title":"JAMA"},{"issue":"1","key":"7982_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12981-022-00459-y","volume":"19","author":"S Zou","year":"2022","unstructured":"Zou S, Wu M, Ming F, Wu S, Guo W, Marley G, et al. Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals. AIDS Res Ther. 2022;19(1):33. https:\/\/doi.org\/10.1186\/s12981-022-00459-y.","journal-title":"AIDS Res Ther"},{"issue":"9","key":"7982_CR21","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","volume":"38","author":"CW Tan","year":"2020","unstructured":"Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, Hu Z, Chen VC, Young BE, Sia WR, Tan YJ, Foo R, Yi Y, Lye DC, Anderson DE, Wang LF. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38(9):1073\u20138. https:\/\/doi.org\/10.1038\/s41587-020-0631-z.","journal-title":"Nat Biotechnol"},{"issue":"10","key":"7982_CR22","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2107715","volume":"385","author":"A Jara","year":"2021","unstructured":"Jara A, Undurraga EA, Gonz\u00e1lez C, Paredes F, Fontecilla T, Jara G, Pizarro A, Acevedo J, Leo K, Leon F, Sans C, Leighton P, Su\u00e1rez P, Garc\u00eda-Escorza H, Araos R. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385(10):875\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2107715.","journal-title":"N Engl J Med"},{"issue":"16","key":"7982_CR23","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/j.vaccine.2019.02.064","volume":"37","author":"C Fritzsche","year":"2019","unstructured":"Fritzsche C, Bergmann L, Loebermann M, Glass A, Reisinger EC. Immune response to hepatitis A vaccine in patients with HIV. Vaccine. 2019;37(16):2278\u201383. https:\/\/doi.org\/10.1016\/j.vaccine.2019.02.064.","journal-title":"Vaccine"},{"key":"7982_CR24","doi-asserted-by":"publisher","DOI":"10.4172\/2155-6113.1000419","author":"DJ Leggat","year":"2015","unstructured":"Leggat DJ, Iyer AS, Ohtola JA, Kommoori S, Duggan JM, Georgescu CA, et al. Response to pneumococcal polysaccharide vaccination in newly diagnosed HIV-positive individuals. J AIDS Clin Res. 2015. https:\/\/doi.org\/10.4172\/2155-6113.1000419.","journal-title":"J AIDS Clin Res."},{"issue":"8","key":"7982_CR25","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.vaccine.2021.01.043","volume":"39","author":"E Seremba","year":"2021","unstructured":"Seremba E, Ocama P, Ssekitoleko R, Mayanja-Kizza H, Adams SV, Orem J, Katabira E, Reynolds SJ, Nabatanzi R, Casper C, Phipps W. Immune response to the hepatitis B vaccine among HIV-infected adults in Uganda. Vaccine. 2021;39(8):1265\u201371. https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.043.","journal-title":"Vaccine"},{"issue":"1","key":"7982_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1089\/dna.2021.0520","volume":"41","author":"E Brenna","year":"2022","unstructured":"Brenna E, McMichael AJ. The importance of cellular immune response to HIV: implications for antibody production and vaccine design. DNA Cell Biol. 2022;41(1):38\u201342. https:\/\/doi.org\/10.1089\/dna.2021.0520.","journal-title":"DNA Cell Biol"},{"issue":"1","key":"7982_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41541-022-00452-6","volume":"7","author":"ZL Brumme","year":"2022","unstructured":"Brumme ZL, Mwimanzi F, Lapointe HR, Cheung P, Sang Y, Duncan MC, et al. Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. NPJ Vaccines. 2022;7(1):28. https:\/\/doi.org\/10.1038\/s41541-022-00452-6.","journal-title":"NPJ Vaccines."},{"key":"7982_CR28","unstructured":"Antinori A CS, Meschi S. Immunogenicity of mRNA vaccination against SARS-CoV-2 in persons living with HIV (PLWHs) with low CD4 count or previous AIDS. 18th European AIDS Conference, EACS.2021, London Abstract OS4\/3."},{"key":"7982_CR29","doi-asserted-by":"publisher","first-page":"833783","DOI":"10.3389\/fpubh.2022.833783","volume":"10","author":"M Wu","year":"2022","unstructured":"Wu M, Ming F, Wu S, Liu Y, Zhang X, Guo W, et al. Risk of SARS-CoV-2 infection among people living with HIV in Wuhan, China. Front Public Health. 2022;10:833783. https:\/\/doi.org\/10.3389\/fpubh.2022.833783.","journal-title":"Front Public Health"},{"issue":"2","key":"7982_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.chom.2022.01.005","volume":"30","author":"S Cele","year":"2022","unstructured":"Cele S, Karim F, Lustig G, San JE, Hermanus T, Tegally H, et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host Microbe. 2022;30(2):154\u201362. https:\/\/doi.org\/10.1016\/j.chom.2022.01.005.","journal-title":"Cell Host Microbe"},{"key":"7982_CR31","unstructured":"The Washington Post. As omicron variant is detected around the world, travel bans may be too late, experts say. https:\/\/www.washingtonpost.com\/world\/2021\/11\/28\/omicron-variant-coronavirus\/. Accessed 29 Nov 2021. 2021."}],"updated-by":[{"DOI":"10.1186\/s12879-024-09913-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000}}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-07982-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-07982-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-07982-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T05:04:33Z","timestamp":1726463073000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-07982-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7982"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-07982-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1750225\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"assertion":[{"value":"12 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12879-024-09913-w","URL":"https:\/\/doi.org\/10.1186\/s12879-024-09913-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the Research and Ethics Committee of Zhongnan Hospital (2020079K-1). All the procedures were performed in accordance with the Declaration of Helsinki, and the patient's confidentiality was maintained throughout the investigation. All individuals provided their written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}